优秀获奖论文

您当前的位置:国医在线 > 国医专题 > 第六届兰茂论坛 > 优秀获奖论文 >

“四四固本颗粒”治疗腹泻型肠易激综合征(脾肾阳虚型)临床研究

2019-10-18 15:39 来源:国医在线 发布人:高燕仙 浏览:

姜莉云1 时岱2 郑玉1 董月秋1 杨翼豪1 周瑞彬1 许云姣1 吴文笛1

(1昆明市中医医院 2无锡市中医医院)

(本论文荣获“第六届兰茂论坛”优秀论文二等奖)

  摘要 目的  观察“四四固本颗粒”治疗腹泻型肠易激综合征(脾肾阳虚型)患者的临床疗效,并评价该药物的安全性。方法  选取2016年4月-2018年4月到本院脾胃病科门诊及住院部的IBS-D(脾肾阳虚型)患者100例,随机分为治疗组和对照组,每组各50例。治疗组予“四四固本颗粒”治疗,对照组给予 “四神丸”治疗,疗程均为2周。分别对两组患者的中医证候量表积分、生活质量量表(IBS-QOL)积分、焦虑自评量表(SAS)积分和抑郁自评量表(SDS)积分进行治疗前后组内及组间比较。结果  治疗组总有效率92%,高于对照组72%,两组比较差异有统计学意义(P﹤0.05);治疗前,治疗组中医证候量表积分、IBS-QOL积分、焦虑自评量表(SAS)积分、抑郁自评量表(SDS)积分分别与对照组比较无明显统计学差别(P﹥0.05);治疗后,两组IBS-QOL量表积分与治疗前比较,差异均具有统计学意义(P<0.05),且两组间比较治疗组优于对照组,差异具有统计学意义(P<0.05);两组SAS量表积分及与SDS量表积分分别与治疗前比较,治疗组均差异显著,具有统计学意义(P<0.05),对照组均无明显差异,无统计学意义(P >0.05),两组间比较治疗组均优于对照组,差异均具有统计学意义(P<0.05)。 结论  “四四固本颗粒”治疗腹泻型肠易激综合征(脾肾阳虚型)安全有效,可以改善临床症状、生存质量以及焦虑抑郁情绪,值得进一步推广使用,并在实验以及药理学分析等方面进行广泛深入的研究。

  关键词:四四固本颗粒;腹泻型肠易激综合征(脾肾阳虚型);IBS-QOL;SAS/SDS

  Clinical Study of "Sisi Guben Granule" in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (Spleen and Kidney Yang Deficiency)

  Jiang Liyun1 Shi Dai2 Zheng Yu1 Dong Yueqiu1 Yang Yihao1 Zhou Ruibin1 Xu Yunjiao1 Wu Wendi1Δ

  (1 Department of Spleen and Stomach Diseases, Kunming Traditional Chinese Medicine Hospital  Kunming  650011;2 Department of Infectious Diseases, Wuxi Traditional Chinese Medicine Hospital  Wuxi  214000)

  Abstract   Objective   To observe the clinical efficacy of "Sisi Guben Granule" in the treatment of diarrhea-predominant irritable bowel syndrome (spleen-kidney Yang deficiency type), and to evaluate the safety of the drug. Method   100 cases of IBS-D (deficiency of spleen and kidney yang) from April 2016 to April 2018 were randomly divided into treatment group and control group, 50 cases in each group. The treatment group was treated with "Sisi Guben Granule" and the control group was treated with "Sishen Pill" for two weeks. The scores of TCM Syndrome Scale, Quality of Life Scale (IBS-QOL), Self-rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS) of the two groups were compared before and after treatment. Result   The total effective rate of the treatment group was 92%, higher than 72% of the control group, and there was significant difference between the two groups (P < 0.05). Before treatment, the scores of TCM syndrome scale, IBS-QOL score, SAS score and SDS score of the treatment group were not significantly different from those of the control group (P > 0.05); after treatment, the scores of IBS-QOL scale of the two groups were not significantly different from those of the control group (P > 0.05). The difference was statistically significant (P < 0.05), and the treatment group was better than the control group, the difference was statistically significant (P < 0.05); SAS scale scores and SDS scale scores of the two groups were significantly different from those before treatment (P < 0.05), and there was no significant difference between the control group and the two groups (P > 0.05), the comparison between the two groups was not significant (P > 0.05). The treatment group was better than the control group, the difference was statistically significant (P < 0.05). Conclusion   "Sisi Guben Granule" is safe and effective in the treatment of diarrhea-predominant irritable bowel syndrome (spleen-kidney Yang deficiency type). It can improve clinical symptoms, quality of life and anxiety and depression. It is worthy of further promotion and application. It has been extensively studied in the aspects of experiment and pharmacological analysis.

  Key Words:Sisi Guben Granules; Diarrhea-predominant Irritable Bowel Syndrome (Spleen and Kidney Yang Deficiency); IBS-QOL; SAS/SDS

  肠易激综合征( Irritable bowel syndrome,IBS) 是一种胃肠道的功能性疾病,该病具有病程时间长,治疗手段单一,难以彻底康复,易反复发作的特点,严重影响患者正常的生活质量,属未引起足够重视且占用大量医疗资源的疾病之一。根据临床上出现的症状不同,罗马Ⅲ将IBS归纳为四个不同的临床分型,即腹泻型(IBS-D)、便秘型、混合型和未定型[1],临床以腹泻型尤为常见。根据目前国内外流行病学调查结果显示,腹泻型肠易激综合征在西方国家的发病率可以达到10%~15%,在我国的发病人数,也占到总人口的5%~10%[2]。腹泻型肠易激综合征是一种男女均易发作的疾病,男女患者比例约为 1∶2[3]。研究表明,由于临床症状的影响,20%-30%的IBS-D患者甚至伴有较为严重的焦虑抑郁症状[4]。笔者以二十余年临床经验为基础,在云南吴氏扶阳流派学术思想指导下,基于对脾肾阳虚型IBS-D病因病机治法的独到理解,自拟“四四固本颗粒”复方,运用于临床百余名患者,取得满意疗效,并获得省市课题立项支持,经过两年的临床研究,现总结汇报如下:

  1    资料与方法

  1.1 临床资料

  1.1.1一般资料  选择2016年4月-2018年4月到昆明市中医医院脾胃病科门诊及住院部的IBS-D(脾肾阳虚型)患者100例。随机分为治疗组和对照组,两组各50例,对照组男性19例,女性31例,平均年龄(40.63±10.86)岁,平均病程(7.33±2.74)年;治疗组男性18例,女性32例,平均年龄(40.40±12.13)岁,平均病程(7.12±2.03)年;两组患者一般资料比较差异无统计学意义(P>0.05),具有可比性。

  1.1.2 诊断标准

  1.1.2.1 西医诊断  符合罗马Ⅲ腹泻型(IBS-D)的诊断标准,以腹泻为主(发作时,>25%的排便呈稀糊便,而<25%的排便呈块样或干硬粪便)

  1.1.2.2 中医诊断  参照《中医病症诊断疗效标准》(ZY/T001.1-94)(泄泻)及中华中医药学会脾胃病分会2009年发布的《肠易激综合征中医诊疗共识》综合本病常见临床证候,确定脾肾阳虚型诊断:主症:晨起泄泻,大便夹有不消化食物;脐腹冷痛,得温痛减;形寒肢冷。次症:腰膝酸软;神疲乏力;不思饮食;舌淡胖,苔白滑;脉沉细。具备以上三点主要临床症状,并符合随意两项次要症状即可诊断。

  1.1.2.3 纳入标准  ①符合IBS-D诊断标准;②符合中医辨证标准;③年龄18岁-65岁之间;④自愿接受治疗并已签署知情同意书者。

  1.1.2.4 排除标准  ①伴有心、脑、肝、肾等其他脏器严重疾病;精神病患者或对本次试验产生影响者;②腹部手术史者;③妊娠及哺乳期妇女;④乙醇依赖者及药物滥用史;⑤近2周曾服用相关治疗药物,如影响结肠动力药物和益生菌制剂;⑥参加其他临床试验者。

  1.2  方 法

  1.2.1治疗方法  基础用药,对合并有高血压、高脂血症、糖尿病的患者给予相关的基础治疗。对照组患者给予“四神丸”(北京同仁堂天然药物有限公司,国药准字 Z13020656),口服,9克/次,3次/天。治疗组给予“四四固本颗粒”(由笔者提供处方,北京康仁堂制药公司研制),药物组成包括:附子干姜党参茯苓、炒白术、吴茱萸、川芎佛手赤石脂、粳米、芡实、炙甘草等十二味中药。1袋/10克/次,开水冲服150—200ml,3次/天。疗程为2周。